Author:
Jiang Shao-Liang,Hu Lu,Hu Zhe-Ying,Wang Wan-Jun,Shi Jie-Hua
Funder
Natural Science Foundation of Zhejiang Province
Zhejiang University of Technology
Subject
Spectroscopy,Instrumentation,Atomic and Molecular Physics, and Optics,Analytical Chemistry
Reference51 articles.
1. M. Menichincheri, E. Ardini, P. Magnaghi, N. Avanzi, P. Banfi, R. Bossi, et al., Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor, J Med Chem. 62 (2019) 8364-8364, Doi:10.1021/acs.jmedchem.9b01259.
2. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors;Liu;Ther. Clin. Risk Manag.,2018
3. LC–MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation;Attwa;J. Pharm. Biomed. Anal.,2018
4. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor, Expert Opin Invest;Rolfo;Drugs,2015
5. Entrectinib: First Global Approval;Al-Salama;Drugs,2019
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献